Becton, Dickinson and Company (BDX) is currently trading at $183.82. Based on 12 Wall Street analysts, the average target price is $195.67, implying a 6.4% upside. The consensus recommendation is BUY.

Over the past 30 days, the feed records 1 target raise and 0 target cuts for BDX. Over the past 90 days, the feed records 8 target raises and 1 target cut for BDX.

BDX

Becton, Dickinson and Company

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$183.82

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$170.00$204.00
Current $183.82
Median: $182.00Mean: $185.67Current: $183.82

Recent price target updates (latest 80)

  • B of A SecuritiesAug 31, 2026

    PT action: Raises

    $185.00 → $200.00

  • RBC CapitalAug 13, 2026

    PT action: Raises

    $180.00 → $190.00

  • CitigroupAug 7, 2026

    PT action: Raises

    $198.00 → $204.00

  • RBC CapitalAug 7, 2026

    PT action: Raises

    $175.00 → $180.00

  • Piper SandlerAug 7, 2026

    PT action: Raises

    $161.00 → $175.00

  • Wells FargoAug 7, 2026

    PT action: Raises

    $161.00 → $170.00

  • TD CowenAug 5, 2026

    PT action: Raises

    $163.00 → $182.00

  • UBSJul 28, 2026

    PT action: Announces

    $0.00 → $190.00

  • Evercore ISI GroupJul 6, 2026

    PT action: Lowers

    $190.00 → $180.00

  • BarclaysMay 11, 2026

    PT action: Raises

    $202.00 → $204.00

  • Wells FargoMay 8, 2026

    PT action: Raises

    $157.00 → $161.00

  • TD CowenMay 4, 2026

    PT action: Lowers

    $189.00 → $163.00

  • Piper SandlerApr 17, 2026

    PT action: Lowers

    $170.00 → $159.00

  • Argus ResearchMar 23, 2026

    PT action: Lowers

    $230.00 → $180.00

  • CitigroupFeb 11, 2026

    PT action: Lowers

    $232.00 → $198.00

  • JP MorganFeb 10, 2026

    PT action: Lowers

    $190.00 → $175.00

  • JefferiesFeb 10, 2026

    PT action: Lowers

    $220.00 → $190.00

  • RBC CapitalFeb 10, 2026

    PT action: Lowers

    $210.00 → $172.00

  • CitigroupFeb 10, 2026

    PT action: Lowers

    $233.00 → $232.00

  • Piper SandlerFeb 10, 2026

    PT action: Lowers

    $205.00 → $170.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$195.67

Based on 12 analysts

Analyst Recommendations

Buy (7)Hold (7)Sell (0)

Upside

+6.44%

Market Cap

$50.07B

Financial & Investment Metrics

Next Earnings Date
Nov 5, 2026D-40
P/E Ratio (TTM)31.86
Forward P/E13.83
P/B Ratio2.05
Dividend Yield2.28%
Return on Equity (ROE)6.61%
Operating Margin15.73%
Debt to Equity68.84
Beta (Volatility)0.28
52 Week Range$127.59 - $193.07
LowCurrent: $183.82High

Daily editorial mentioning BDX

Price target moves

CSCO Targets Raised by Four Firms as Truist Cuts Nine Utilities

Exactly 21 distinct tickers on our curated watchlist experienced firm-level target price adjustments over the past 14 days, according to consensus data finalized on August 13, 2026, at 11:48 PM UTC. The bi-weekly stretch revealed a stark contrast between selective optimism in the information technology and industrials sectors and a systematic re-evaluation of utility operators. While several tech and defense names saw their price targets marched higher, a broad sweep of downward revisions hit power and gas providers, illustrating how different pockets of the large-cap space are being reassessed by major research desks.

Target changes

The most concentrated cluster of upward revisions focused on Cisco Systems, which drew higher price targets from four separate institutions. Wells Fargo led the charge, boosting its target on the tech giant from 130 to 150, while Truist Securities pushed its valuation from 125 to 140. UBS and Barclays also stepped up their targets to 138 and 123, respectively. This collective shift suggests a growing alignment among analysts regarding the company's valuation floor.

Beyond technology, defense and aerospace giants saw notable upward adjustments from Citigroup. The firm raised its target on Northrop Grumman from 617 to 667 and simultaneously lifted Lockheed Martin from 641 to 691. Healthcare also enjoyed positive attention as Wolfe Research initiated or adjusted coverage on AbbVie with a 300 target and Abbott Laboratories at 130, while RBC Capital nudged Becton Dickinson from 180 to 190. In the energy patch, Wells Fargo adjusted its targets upward for Permian Resources from 26 to 27 and APA Corporation from 39 to 49.

Conversely, the downgrades were dominated by a sweeping campaign from Truist Securities across the utilities sector. The firm adjusted its targets downward for nine different utilities, trimming Xcel Energy from 94 to 88, WEC Energy Group from 122 to 114, Sempra from 107 to 100, Southern Company from 100 to 97, Public Service Enterprise Group from 90 to 84, Exelon from 50 to 48, Entergy from 129 to 122, Dominion Energy from 68 to 66, and Atmos Energy from 188 to 179. Outside of utilities, Citigroup significantly cut its target on Intuit from 591 to 457, and Freedom Broker slashed its target on Mosaic from 32 to 17.

Ticker Firm Dir Prior→Current
CSCO Wells Fargo Up 130→150
INTU Citigroup Down 591→457
LMT Citigroup Up 641→691
MOS Freedom Broker Down 32→17

For a complete breakdown of these adjustments and to track real-time revisions as they occur, investors can monitor the comprehensive market moves page.

How this differs from consensus

The relationship between individual analyst revisions and the broader consensus mean reveals some intriguing anomalies. For instance, even after Citigroup's drastic cut of Intuit's target to 457, the stock still boasts an implied consensus upside of 26%. This indicates that Citigroup has taken a significantly more conservative posture than the broader street, which remains anchored to higher historic valuations. Similarly, Freedom Broker's aggressive cut on Mosaic to 17 leaves the stock with a 26.5% upside relative to its consensus mean, suggesting the firm is moving ahead of a slower-to-react analyst herd in the materials sector.

In contrast, the materials sector also produced a valuation anomaly with Packaging Corporation of America. UBS upgraded its target to 292, yet the stock's implied upside sits at -0.1%. This negative spread tells us that the equity has already run hard enough to eclipse even newly elevated expectations, leaving virtually no margin for error.

Meanwhile, the aerospace and defense adjustments show Citigroup attempting to keep pace with a sector that has steady momentum. Northrop Grumman’s new 667 target leaves it with a comfortable 12.3% consensus upside, whereas Lockheed Martin’s bump to 691 leaves it with a much tighter 5.4% upside. This divergence suggests that while both defense names are viewed favorably, Northrop Grumman is perceived to have significantly more valuation runway left. The uniform downgrades in utilities by Truist, though numerous, still leave many of those names with double-digit implied upsides, such as Sempra at 21.1% and Xcel at 17%, indicating that while targets are coming down, the sector's defensive yield profile continues to support a positive consensus outlook.

Read article →

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
8/26/2026FELD MICHAELOfficerSale at price 188.49 per share.165
8/13/2026POLEN THOMAS E JRChief Executive OfficerSale at price 185.00 per share.4,152
8/11/2026GOETTE ROLANDOfficerSale at price 180.84 per share.2,438
7/27/2026FELD MICHAELOfficerSale at price 157.13 per share.75
6/26/2026FELD MICHAELOfficerSale at price 152.80 per share.75
6/24/2026GARRISON MICHAEL DAVIDOfficerSale at price 145.66 per share.1,100
6/10/2026GARRISON MICHAEL DAVIDOfficerSale at price 151.48 per share.1,100
6/1/2026POLEN THOMAS E JRChief Executive OfficerSale at price 146.35 per share.2,764
5/26/2026FELD MICHAELOfficerSale at price 147.35 per share.75
4/27/2026FELD MICHAELOfficerSale at price 151.94 per share.74

Frequently Asked Questions

Q. What is the current target price and upside for BDX?

A. The current target price for Becton, Dickinson and Company is $195.67, which implies a 6.4% upside from the current price of $183.82. This is based on the consensus of 12 Wall Street analysts.

Q. What is the current analyst recommendation for BDX?

A. Currently, there are 1 Strong Buy, 6 Buy, 7 Hold, 0 Sell, and 0 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying BDX stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer →